Literature DB >> 18323764

Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?

Laura B Zahodne1, Hubert H Fernandez.   

Abstract

It is essential to recognize and treat psychosis in Parkinson's disease for several reasons. Studies have shown that psychosis in Parkinson's disease patients is a strong risk factor for nursing home placement. Psychosis may be the greatest source of stress for caretakers of Parkinson's patients; it is often persistent, and its presence markedly increases mortality. Treatment of psychotic symptoms should occur only after potential medical and environmental causes of delirium have been eliminated or addressed. Initial pharmacologic changes should include limiting the patient's antiparkinsonian medications to those that are necessary to preserve motor function. Should that fail, an atypical antipsychotic is presently the treatment of choice. An emerging treatment option is acetylcholinesterase inhibitors. This article reviews what is currently known about the course, prognosis, and treatment strategies in Parkinson's disease psychosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18323764      PMCID: PMC3045851          DOI: 10.1017/s1092852900017296

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  83 in total

1.  Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Authors:  William G Ondo; Ron Tintner; Kevin Dat Voung; Dejian Lai; George Ringholz
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

Review 2.  Novel pharmacological targets for the treatment of Parkinson's disease.

Authors:  Anthony H V Schapira; Erwan Bezard; Jonathan Brotchie; Frédéric Calon; Graham L Collingridge; Borris Ferger; Bastian Hengerer; Etienne Hirsch; Peter Jenner; Nicolas Le Novère; José A Obeso; Michael A Schwarzschild; Umberto Spampinato; Giora Davidai
Journal:  Nat Rev Drug Discov       Date:  2006-10       Impact factor: 84.694

3.  Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.

Authors:  E Mohr; T Mendis; K Hildebrand; P P De Deyn
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

4.  Mental symptoms in Parkinson's disease are important contributors to caregiver distress.

Authors:  D Aarsland; J P Larsen; K Karlsen; N G Lim; E Tandberg
Journal:  Int J Geriatr Psychiatry       Date:  1999-10       Impact factor: 3.485

5.  Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.

Authors:  Christopher G Goetz; Joanne Wuu; Linda M Curgian; Sue Leurgans
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

6.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

7.  Aripiprazole and Parkinson's disease psychosis.

Authors:  Carlos Schönfeldt-Lecuona; Bernhard J Connemann
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

8.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

Authors:  C G Goetz; G T Stebbins
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

9.  Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.

Authors:  G Fabbrini; P Barbanti; C Aurilia; C Pauletti; G L Lenzi; G Meco
Journal:  Neurol Sci       Date:  2002-04       Impact factor: 3.307

10.  Pharmacology of hallucinations induced by long-term drug therapy.

Authors:  C G Goetz; C M Tanner; H L Klawans
Journal:  Am J Psychiatry       Date:  1982-04       Impact factor: 18.112

View more
  4 in total

Review 1.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 2.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

Review 3.  Neuropsychiatric symptoms in Parkinson's disease.

Authors:  Dag Aarsland; Laura Marsh; Anette Schrag
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

Review 4.  Relationship between Apolipoprotein Superfamily and Parkinson's Disease.

Authors:  Lin Li; Ming-Su Liu; Guang-Qin Li; Jie Tang; Yan Liao; Yang Zheng; Tong-Li Guo; Xin Kang; Mao-Ting Yuan
Journal:  Chin Med J (Engl)       Date:  2017-11-05       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.